Objective: We sought to identify immunologic and virologic correlates of spontaneous viral control among long-term survivors of perinatal HIV infection expressing the protective human leukocyte antigen (HLA)-B57 allele.
Introduction
Expression of particular class I human leukocyte antigen (HLA) alleles, primarily those at the HLA-B locus [1] , exerts a strong influence on the rate of progression to AIDS that is consistent across multiple cohorts [2] [3] [4] [5] [6] [7] . The strongest and most reproducible of these associations is with HLA-B57, which is present in 44-85% of 'elite controllers' who spontaneously control plasma HIV RNA levels to less than 50 copies/ml in the absence of antiviral therapy [8, 9] . Yet, this allele is also present in 10% of adults with progressive HIV infection [8, 9] , indicating that expression of B57 alone is not sufficient for elite control. Despite extensive studies, the molecular mechanism by which HLA-B57 confers the ability to spontaneously control viremia in some, but not all, HIV-infected individuals remains unclear.
HLA-B57-restricted CD8 T-cell responses are highly immunodominant [10, 11] , but the frequency of HIVspecific cytotoxic T lymphocytes restricted by this allele does not differ between adults who spontaneously control viremia and those with high viral loads and progressive infection [12] . Extensive characterization of CD8 responses to HIV in adult controllers has revealed CD8 subpopulations displaying functional attributes, such as preserved proliferative capacity [12] , simultaneous production of multiple cytokines [13] , and enhanced effector molecule loading [14] , that are not observed among individuals with higher levels of viremia. However, it can be difficult to discern from such studies whether this functional superiority is a cause or consequence of restricted viral replication. Additional studies have detailed viral sequences changes selected by B57-mediated immune pressure that incur a cost to viral replicative capacity [15] [16] [17] [18] . Nonetheless, progression to AIDS occurs in many B57-positive individuals in whom these fitness-attenuating viral mutations are observed.
We examined a unique cohort of B57-positive long-term survivors -children and adolescents who have lived longer than 10 years following perinatal HIV infectionto identify viral and immunologic factors that are associated with sustained and spontaneous control of HIV viremia to low levels in the absence of antiretroviral therapy.
Patients and methods

Study participants
Eleven HLA-B57-positive long-term survivors of perinatal infection with clade B HIV-1 were recruited at Children's Hospital in Boston, Boston Medical Center, the National Cancer Institute, Queen Elizabeth Hospital in Barbados, and University of the West Indies in Jamaica. Clinical, CD4, and HIV viral load data at the time of evaluation are displayed in Table 1 . High-resolution class I HLA typing was performed by sequencing. This study was approved by the Institutional Review Boards at Massachusetts General Hospital and at all collaborating institutions. All participants and/or guardians signed written informed consent prior to participation.
HIV-1 peptides corresponding to all known HIV-1 optimal epitopes in the Los Alamos HIV Molecular Immunology Database (with an expanded list of 16 HLA-B57-restricted epitopes [19] ) were synthesized on an automated synthesizer at the Massachusetts General Hospital Peptide Core Facility using 9-fluorenylmethoxy carbonyl chemistry. Participants were screened for recognition of optimal epitopes restricted by HLA-B57 and their other HLA alleles (range 3-24 non-B57 optimals tested per participant). Peptides corresponding to autologous variant sequences within B57-restricted Gag epitopes (TW10, KF11, QW9, and ISW9) were also 1426 AIDS 2010, Vol 24 No 10 Multiparameter intracellular cytokine staining assay Cryopreserved PBMCs were thawed, rested overnight, examined for viability by trypan blue exclusion, and aliquoted at 10 6 viable PBMCs per tube with anti-CD28 and CD49d (1 mg/ml each) and fluorescein isothiocyanate-conjugated anti-CD107a antibodies. Cells were stimulated with HIV peptides (2 mg/ml) for 6 h at 378C. Brefeldin A (1 mg) and monensin (0.6 mg) were added after the first hour. Following stimulation, samples were washed and stained with blue Cell Viability Dye (Invitrogen/Molecular Probes Inc., Eugene, Oregon, USA). Cells were then stained with fluorescently labeled antibodies to CD3 (Pacific Blue; Molecular Probes Inc.), CD4 (allophycocyanin; APC), and CD8 (APC-Cy7). After surface staining, cells were fixed and permeabilized (CALTAG Fix & Perm Medium A and B; /Invitrogen, Camarillo, California, USA) and then stained with antibodies against intracellular cytokines IFNg (PE-Cy7), tumor necrosis factor a (TNFa) (Alexa Fluor 700; Molecular Probes Inc.), and interleukin-2 (IL-2) phycoerythrin. Each assay included a positive control containing phytohaemagglutinin (1 mg/ml) and a negative control with no peptide. Antibodies and protein transport inhibitors were obtained from BD Biosciences (San Jose, California, USA).
Flow cytometry acquisition and analysis Data were acquired within 6 h of staining on an LSR II cytometer using FACSDiva software (BD BiosciencesImmunocytometry Systems, version 4.1.2), with bead compensation (Becton Dickinson, Franklin, Lakes, New Jersey, USA), and analyzed using FlowJo (TreeStar Inc., Ashland, Oregon, USA). Pie charts were generated using SPICE 4.1.6 and Pestle f software (kindly provided by Mario Roederer; Vaccine Research Center, NIH, Bethesda, Maryland, USA). A lymphocyte gate was set based on forward-scatter and side-scatter, and CD3 þ events were gated to remove dead cells stained with the blue Cell Viability Dye. The frequency of CD8 þ T cells producing each cytokine (or degranulating) was determined by subtracting the percentage of cytokine-positive cells in the unstimulated CD28/49d control tube from that of each peptide-stimulated tube. Boolean gating was used to create the full array of 16 possible response patterns.
Viral sequencing
Population sequencing of the full HIV-1 genome was performed from plasma using the QIAamp Viral RNA Mini Kit (Qiagen GmbH, Hilden, Germany) following amplification by nested PCR (inner and outer primer sets and PCR conditions as previously described) [20] . The PCR products of the secondary reaction were purified and sequenced directly using the ABI 3100 DNA Analyzer from Applied Biosystems Inc. (Foster City, California, USA). The HXB2 numbering system is used to specify individual amino acid residues. Viral sequences could not be amplified from progressor CH-14.
Statistical analysis was performed using Stata Statistical Software, release 8.0 (StataCorp, College Station, Texas, USA). Two-group comparisons were performed using the Wilcoxon rank-sum test and categorical outcomes were compared using Fisher's exact test. All tests were two-tailed, with P value less than 0.05 considered as significant.
Results
Long-term survival among B57-positive children following perinatal HIV infection Eleven perinatally HIV-infected HLA-B57-positive patients ranging in age from 10 to 21 years were identified. Four participants, termed 'spontaneous controllers', were clinically asymptomatic and maintained HIV RNA levels less than 3000 copies/ml in the absence of therapy. Two of these spontaneous controllers (CH-04 and CH-22) were naive to antiretroviral therapy. Patient CH-13 had briefly received didanosine monotherapy during infancy before being lost to follow-up for 6 years, and subsequently presented with an HIV RNA level of 620 copies/ml at 9 years of age. Patient CH-03 discontinued dual nucleoside reverse transcriptase inhibitor (NRTI) therapy with azidothymidine and didanosine at age 13 and subsequently maintained a viral load less than 1000 copies/ml for more than 5 years. Each of these patients maintained a normal CD4 percentage of higher than 25% [21] . The remaining seven patients, termed 'treated progressors', had begun antiretroviral therapy due to clinical disease progression and/or elevated viremia at a median age of 8 years (range 7-13). All had documented HIV RNA levels higher than 10 000 copies/ml before starting antiviral therapy, but comprehensive data regarding the early clinical course were not available for all patients and it is possible that some may have fit the spontaneous controller definition at an early stage of their infection. In response to antiviral therapy, HIV RNA levels were low in all treated progressors at the time of study (<50 to 4017 copies/ml; Table 1 ). Spontaneous controllers and treated progressors did not statistically differ with respect to age (P ¼ 0.34).
Sustained spontaneous control of viremia is characterized by a narrower T-cell response
Patients were tested by IFNg ELISPOT for recognition of all optimal epitopes restricted by their class I HLA alleles (both B57 and non-B57 epitopes) that were listed in the 2006 HIV Molecular Immunology Database. Despite longstanding infection, the response to B57-restricted epitopes dominated the total T-cell response to HIV among both spontaneous controllers and treated progressors. Among the entire cohort, 67% of HIV epitopes targeted, and 74% of HIV-specific cells, were restricted by HLA-B57. Although this dominance was slightly more pronounced among spontaneous controllers than in treated progressors, the difference did not achieve statistical significance (Fig. 1a) . Spontaneous controllers recognized significantly fewer of the 16 B57-restricted HIV-1 epitopes than progressors (median 2.5 vs. 7; P ¼ 0.044) and the frequency of T cells specific for B57-restricted epitopes was also lower among controllers, although this difference did not achieve statistical significance (median 2350 vs. 6750 SFCs/million PBMCs; P ¼ 0.163). When responses to optimal epitopes restricted by all HLA alleles were compared, a similar pattern was observed, with controllers exhibiting a reduced magnitude and breadth of response relative to treated progressors, despite the very low levels of HIV viremia in both groups (Fig. 1b and Supplementary Table S1, http://links.lww. com/QAD/A26).
Responses to stimulation by optimal peptides may not accurately represent the virus-specific response in individual patients due to amino acid sequence mismatches between the peptides used for stimulation and the virus replicating in the host. We have previously reported that T-cell responses to autologous variant epitopes may be detectable when a response to the 'consensus' epitope is not [22] . Therefore, we also assessed recognition of peptides corresponding to autologous sequence variants of the four B57-restricted Gag epitopes. None of these chronically infected children recognized the consensus version of epitope TW10-Gag, which is immunodominant during acute infection [10] , but responses to the autologous TW10-Gag variant were present in the majority of both spontaneous controllers and treated progressors and exceeded the consensus optimal peptide response in magnitude, as previously described [22] . KF11 peptide variants were recognized less well than the corresponding optimal peptide in the two patients exhibiting mutations in this epitope, with more than 1 log increase in the peptide concentration required to elicit the half-maximal response (Fig. 2a) . Among the four patients who recognized QW9-Gag, responses to the common E180D variant peptide were similar in magnitude, and nonresponders to the consensus optimal failed to recognize the variant as well (Fig. 2b) . Similarly, the I147L substitution in ISW-Gag did not appreciably impact recognition, although the upstream antigen processing mutation A146P may diminish recognition of this epitope in vivo, an effect that is not detected by peptide-stimulation assays (Fig. 2c) [23] . Thus, among all four B57-restricted epitopes in Gag, only TW10 variants were recognized in the absence of a response to the corresponding optimal epitope. Taking into account these variant-specific responses, the breadth of the B57-restricted CD8 response remained significantly lower in spontaneous controllers.
Narrow response to conserved regions of Gag and reverse transcriptase is associated with spontaneous control of viremia All four B57-positive spontaneous controllers recognized only a limited number of epitopes in Gag and reverse transcriptase. Each of these epitopes was targeted frequently by progressors as well; thus, durable viral control in the absence of antiviral therapy could not be attributed to recognition of any single critical antigenic determinant. Interestingly, epitopes within other HIV proteins (Nef, Integrase, Vif, Vpr, and Rev) were targeted exclusively by treated progressors (Fig. 1d) . Overall, these data support prior observations from adult studies, suggesting that spontaneous controllers preferentially target a limited number of epitopes within conserved regions of the virus [8] . Because samples from early in the disease course were available for only a limited number of patients, we were unable to explore the hypothesis that treated progressors had experienced a broadening of responses coincident with rising viremia, as has been described following viral escape from the immunodominant HLA-B27 epitope KK10-Gag [24] .
CD8 T-cell cytokine production patterns vary in response to different B57-restricted epitopes and do not correlate with spontaneous viral control As recognition of particular B57-restricted epitope(s) was not associated with spontaneous control of viremia, we explored the hypothesis that the functional capacity of B57-restricted CD8 T cells, rather than their epitope specificity, enables B57-positive patients to spontaneously control viremia. Previous studies have concluded that 'polyfunctional' CD8 cells capable of producing multiple cytokines are preferentially maintained in HIV-positive controllers [13, 14] . We, therefore, assessed the ability of CD8 T cells to degranulate and to secrete multiple cytokines (IFNg, TNFa, and IL-2) following stimulation with peptides corresponding to B57-restricted optimal epitopes [25] . This analysis revealed marked differences in the profile of cytokines produced by CD8 T cells targeting different B57-restricted epitopes, even within the same patient (Fig. 3a) . For instance, patient CH-11 exhibited a highly polyfunctional response to KF11, with degranulation and coproduction of IFNg and TNFa, whereas the response to QW9 in the same assay was markedly dysfunctional with little cytokine production by degranulating cells.
To minimize heterogeneity, we focused our further analyses on the most frequently recognized epitopes, KF11 and ISW9. Nonetheless, marked differences in the functional response profile of KF11-specific and ISW9-specific CD8 cells were observed among patients. Although antigen-specific cells exhibiting three or four simultaneous effector functions were observed, such cells were not detected more frequently among spontaneous controllers than among treated progressors. Interestingly, the patient with the most polyfunctional CD8 T cells and HLA-B57 and perinatal HIV infection Tang et al. 1429 the highest mean fluorescence intensity of cytokine staining was a progressor who had been on suppressive antiviral therapy for 4 years (Fig. 3b) . Together, these data indicate that with respect to cytokine production, B57-restricted HIV-specific CD8 cells were not functionally superior in long-term survivors with spontaneous control relative to those whose viremia is controlled by HAART.
Sequence mutations within B57-restricted HIV epitopes To determine the relationship between HIV sequence variation, epitope recognition, and spontaneous control of viremia, the gag, nef, and pol genes were sequenced from plasma RNA. As has been observed in adult studies, sequence variation within B57-restricted epitopes was common, with a median of nine mutations per patient (Table 2) . Treated progressors and spontaneous controllers did not differ with regard to the total number of mutations observed within epitopes in Gag (median 4 vs. 4.5; P ¼ 0.82), nef (2.5 vs. 3.5; P ¼ 0.23), reverse transcriptase (1 vs. 1; P ¼ 1.00), or all regions combined (8.5 vs. 9.5; P ¼ 0.28). All intra-epitope sequence variants that were commonly observed in treated progressors were observed in the controller group as well. Moreover, no epitope was observed in 'consensus' form more frequently in controllers than in progressors, and the total number of B57-restricted epitopes whose sequence remained 'consensus' did not differ between the two groups. Thus, it is unlikely that the shift toward recognition of CD8 T-cell targets within accessory and [22] .) Variants of KF11 were recognized with lower avidity than the wild-type epitope, but no consistent impact of sequence variation within ISW9 or QW9 was noted. regulatory proteins observed in treated progressors can be attributed to viral escape alone.
Well characterized mutations conferring escape from B57-restricted Gag epitopes TW10 and ISW9 were present in both spontaneous controllers and treated progressors. All patients, except for a single controller, exhibited the T242N mutation in p24-Gag, which is consistently selected for during early infection and has been demonstrated to attenuate viral fitness [10, 15, 16, 25] . This patient (CH-13) exhibited an uncommon mutation within the TW10 epitope (248D), which is associated with a marked reduction in the viral replication rate [26] and likely represents an alternative pathway to escape from this epitope. Numerous studies have shown that following selection for T242N, additional mutations at interacting sites in p24 (residues 219, 223, and 228) accumulate and serve to 'compensate' for the fitness-reducing impact of this epitope [15] [16] [17] 25] . We examined these residues to determine whether the accumulation of such 'compensatory' mutations was associated with loss of spontaneous viral control in our cohort (Table 2) . Strikingly, all treated progressors demonstrated the amino acid substitutions H219Q and M228I/L and most demonstrated I223V as well, whereas none of these mutations were observed in any controller. Sequence variation within the immunodominant epitope KF11, which rarely escapes in clade B infection [27] , was observed in two controllers but no in treated progressors. Patient CH-22 exhibited the A163X mutation, which has been shown to confer immune escape and a subtle fitness cost [27] , but lacked the S165X mutation, which partially compensates for this fitness defect [18] . Sequences from CH-13 -the child with the rare TW10 mutation -displayed an unusual substitution within KF11 as well, suggesting that mutational pathways to escape from these two epitopes may be interdependent. Mutations within or adjacent to the ISW9 epitope were observed in all patients; the 146P processing escape mutation was more common in controllers, whereas the intra-epitope A147L mutation was more common in progressors, although these differences did not achieve statistical significance (P ¼ 0.191 and P ¼ 0.133, respectively). When p24 compensatory mutations were taken into account, both the number of total B57-associated mutations (P ¼ 0.048) and the number of B57-associated gag mutations in (P ¼ 0.03) were significantly higher in treated progressors. Together, these cross-sectional data indicate that extensive variation with B57-restricted epitopes accumulates in both spontaneous controllers and progressors, but in the latter group, additional mutations have emerged that compensate for the fitness defect induced by TW10 escape.
Discussion
In this cross-sectional study, we examined viral and immunologic factors associated with sustained and 1432 AIDS 2010, Vol 24 No 10 Table 2 . Sequence variation within B57-restricted HIV epitopes and T242N-associated compensatory mutations. 
Epitopes in Gag, Nef, and reverse transcriptase are displayed; dashes represent preservation of the wild-type residue indicated in the column heading. Viral sequences could not be amplified from progressor CH-14.
a The amino acid residue preceding epitope B57-ISW9 is included in this table because substitution of proline (P) for the wild-type alanine (A) residue at this site has been shown to confer immune escape via altered antigen processing.
spontaneous control of HIV viremia in the absence of antiviral therapy, which is an exceptionally rare outcome in pediatric infection. The overall rate of progression to AIDS is more rapid following perinatal HIV infection. Without antiviral therapy, fewer than 8% of HIV-positive children survive to age 8 without significant immunocompromise [28] . Thus, the four B57-positive spontaneous controllers described here are highly unusual, as they maintained low levels of viremia as well as high CD4 percentages despite 10-17 years of infection. We have previously shown that most HLA-B57-positive infants control viremia to low levels during infancy and early childhood [25] . In this study, we examined correlates of spontaneous viral control after 10 or more years of infection in B57-positive children, two-thirds of whom had experienced disease progression. It is important to note that the terms 'spontaneous controllers' and 'treated progressors' may denote two different stages of HIV infection rather than two distinct populations of individuals. Indeed, the relatively late age at which most progressors in this study initiated HAART suggests that these children had a benign early clinical course, and some may have met the 'spontaneous controller' definition at an earlier stage.
Our results indicate that neither the specificity of epitopes targeted nor the functional qualities of the responding CD8 T cells differ between spontaneous controllers and treated progressors by the assays employed. In agreement with prior studies of B57-positive adults, the CD8 response of spontaneous controllers was notable for its narrow focus on a small number of epitopes in conserved regions of p24-Gag [8] and reverse transcriptase. The frequency of HIV-specific cells, both B57-restricted and overall, was higher among progressors, despite the fact that most progressors had undetectable viremia on HAART. Because antiviral therapy is known to diminish the magnitude and breadth of virus-specific T-cell responses [14, 20, 29] , the use of HAART by progressors would be expected to bias our analysis toward the null hypothesis. Although all patients in the current study had low levels of viremia, HIV RNA levels were more than 50 copies/ml in all spontaneous controllers but in only a minority of treated progressors. Therefore, the low frequency of HIV-specific cells observed in spontaneous controllers cannot be readily attributed to a lack antigenic stimulation and was more likely related to the restricted breadth of response, as epitope-specific cell frequencies were similar between the groups. The association of spontaneous viral control with a relatively narrow breadth of targeted epitopes has been convincingly established in both B57-positive patients [8] and the general population of HIV controllers [9] . We have previously shown in the setting of HLA-B27 expression that escape from the immunodominant CD8 response is associated with both loss of spontaneous viral control and a coincident broadening of the T-cell epitopes targeted [24] . Longitudinal studies are needed to determine whether a progressive broadening of responses accompanies loss of spontaneous viral control in B57-positive individuals.
A population of 'polyfunctional' HIV-specific T cells, capable of degranulation and simultaneous production of multiple cytokines, has been described in some adult HIV controllers but not in those with untreated progressive infection [30] . Using similar assays, we observed significant functional heterogeneity between patients, as well as heterogeneity in the response to distinct epitopes within the same patient. Overall, however, the cytokine profile of epitope-specific CD8 T cells was not superior among spontaneous controllers, although the small number of patients studied limits the power of this analysis. Intrapatient heterogeneity in the response to different viral epitopes has been previously described in a study by Streeck et al. [31] , which found progressive loss of CD8 cell function to correlate with persistent antigen exposure. However, in our cohort, the degree of polyfunctionality did not correlate with levels of residual viremia nor with sequence variation in the targeted epitope. As reported by Streeck et al., we observed polyfunctional CD8 populations among patients with prolonged HAART-mediated viral suppression, raising the question of whether polyfunctional responses that have been observed in elite controllers are a cause or a consequence of restricted viral replication [13] . Additional parameters of CD8 T-cell function that were not assessed in this study, such as proliferative capacity [12] , effector molecule content, and per-cell cytotoxicity [14] , might be better able to discriminate CD8 populations that contribute to sustained and effective control of viremia.
Viral sequence analysis revealed clear differences between treated progressors and spontaneous controllers. Although mutations accumulated within B57-restricted epitopes in both groups, p24 compensatory mutations that mitigate the fitness-attenuating impact of the T242N mutation were observed only in treated progressors. Prior studies have demonstrated that biologically cloned HIV-1 variants derived from long-term nonprogressors and treated progressors differ in their replication capacity in vitro [32] , that stereotypic B57-driven p24 escape mutations (including T242N) reduce viral replication rates in an additive fashion [33] , and that an associated cluster of mutations in p24 partially offset the fitness deficit incurred by T242N [17] . In the present study, we observed that accumulation of these compensatory mutations during natural infection is associated with loss of spontaneous control of viremia. This difference is not readily attributable to antiviral treatment in the progressor group, as HAART decreases viral replication and hence would be expected to minimize rather than increase the accumulation of viral mutations. Our findings support a prior report that the presence of two or more compensatory mutations is associated with HIV progression [32] . We have also observed that transmitted compensatory mutations are associated with levels of viremia during early infection and may influence the propensity of T242N to revert following transmission to B57-negative hosts [25] . Together, these data indicate that T242N-associated compensatory mutations can nullify the protective impact of HLA-B57 expression, whether they are transmitted or are selected during chronic infection.
Longitudinal studies are needed to examine the temporal relationship between emergence of B57-associated mutations and loss of spontaneous viral control. Our data are consistent with the hypothesis that superior control of viremia in B57-positive patients is facilitated by escape mutations within Gag epitopes, particularly T242N, and that control persists until the subsequent emergence of compensatory mutations that restore fitness, eventuating in increased viral replication and disease progression.
